Technology
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Videos
    • Research
    • Patent Portfolio
    • Consumer Products
  • Licensing Opportunities
  • Investors
    • Overview
    • News & Events
    • Presentations
    • Company Info
    • Analyst Coverage
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Legend Removal
    • Governance
  • Education
    • Background
    • Resources
    • General FAQs
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2022 Annual General Meeting
    • FAQ
  • Analyst Coverage
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Board of Directors
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Aug 07, 2018 6:30am EDT

Lexaria Bioscience Announces Further Advancement of Edibles Nicotine Testing: Delivery Measured Within Minutes

Aug 01, 2018 6:15am EDT

Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered TurboCBD (TM) Capsules

Jul 31, 2018 6:20am EDT

Lexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages

Jul 03, 2018 12:30pm EDT

Lexaria Announces 2018 AGM Results and Corporate Update

Jun 29, 2018 6:15am EDT

Lexaria Files New Patent Application for Enhancement of Delivery of Lipophilic Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders

Apr 30, 2018 4:05pm EDT

Lexaria Technology Brings "Fast-Acting" to Nuka’s 1906 Cannabis Products with 10-Year Deal Consummating Proof-of-Concept Relationship

Apr 17, 2018 5:40am EDT

Lexaria Achieves Significant Breakthrough in Alternative Nicotine Delivery Technology

Mar 13, 2018 8:00am EDT

Lexaria Bioscience Corp. Completes Successful Skin Absorption Study

Mar 12, 2018 10:15am EDT

Chris Bunka, CEO of Lexaria Bioscience Corp., Returns to Uptick Newswire's "Stock Day" Podcast with Everett Jolly to Discuss New Products and Company Evolution

Dec 18, 2017 8:00am EST

Uptick Newswire “Stock Day” Interviews CEO of Lexaria on Cannabis Related Products and Recent Bioscience Patents

  • Previous
  • 1…
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
medical cannabinoid research Lexaria Bioscience Corp. | Medical Cannabinoid Research | Home Logo

Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

  • Home
  • About
  • Technology
  • Licensing Opportunities
  • Investors
  • News
  • Blog
  • Education
  • Events
  • Contact

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright © 2022 All rights reserved. Web Design, Kelowna Photographers, SEO by Hiilite